Novavax Reports Second Quarter 2009 Financial Results
... compared to December 31, 2008.
Since the first
quarter, Novavax continued to advance its vaccine ...
Specific accomplishments since the first
quarter included the following:
"Our progress since the first
quarter has been transformational," said Novavax ...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... for the same period in 2008. Results for the first
six months of 2009 included non-cash charges ... were $3,698,885 compared to $2,986,503 for the first
six months of 2008, including non-cash ... General and administrative expenses for the first
six months of 2009 totaled $1,114,470 compared to ...
Synthetech Reports First Quarter Fiscal 2010 Results
... NZYM) today announced financial results for the first
quarter of fiscal 2010, which ended June 30, ... compared to revenue of $4.9 million in the first
quarter of fiscal 2009. Operating income for the ... or $0.07 per basic share, compared to last year's first
quarter net income of $295,000, or $0.02 per ...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... that positions us for potential approval in the first
review cycle. Our Marketing Authorization ... expect to submit the MAA for pirfenidone in the first
quarter of 2010."
Mr. Welch continued, ... that our partner Roche will enroll the first
patient in our Phase 2b study of ITMN-191 in ...
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Revenue for the first
six months of 2009 totaled $17.9 million, compared with $23.4 million for the first
six months of 2008.
Cost of product and services revenues for the first
six months of 2009 was $6.6 million, compared ...
OncoGenex Reports Second Quarter 2009 Financial Results
... due to manufacturing costs incurred in the first
six months of 2009 associated with the ... takeover of Sonus. Reducing the expenses in the first
six months of 2008 was a Scientific Research and ... to provide a business update and discuss the first
quarter results. A live webcast will be available ...
Telik Announces Second Quarter 2009 Financial Results
... June 30, 2008. Total operating expenses for the first
six months of 2009 were $14.0 million, compared with $21.6 million for the first
six months of 2008. Operating expenses in the first
six months of 2009 included approximately $1.3 ...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
... second quarter of 2008 and 4% as compared to the first
quarter of 2009. Excluding the impact of foreign ... increased by approximately 2% as compared to the first
quarter of 2009. Excluding the impact of foreign ... did not have an impact on the change from the first
quarter of 2009.
The decline in our Base ...
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
... (Nasdaq: RGEN ) today reported results for the first
quarter fiscal year 2010, ended June 30, 2009. ... compared to total revenue of $13,660,000 for the first
quarter of fiscal year 2009. The prior year ... the April 2008 patent licensing agreement. Total first
quarter fiscal year 2010 revenue was comprised of ...
PDI Reports 2009 Second Quarter Financial Results
... PDI, Inc., stated, "While we recognize that the first
half of the year has been difficult, with ... and $10.3 million for the second quarter and first
six months, respectively, we are working ... strategic shift in outsourced sales, the first
half of 2009 was particularly challenging for our ...
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
... of 12,039,794 shares of common stock during the first
quarter of 2009 pursuant to a private placement ... direct offering of common stock during the first
quarter of 2008. The per share amounts for three ... pursuant to a private placement in the first
quarter of 2009 and
9,240,307 shares of ...
GeoVax Labs, Inc. Provides Clinical Studies Update
... begin this trial, assuming FDA approval, in the first
quarter of 2010."
Preventative Clinical ... to Phase 2 is a significant step for GeoVax. The first
injections for the Phase 2a trial were conducted ... trial will be conducted locally in Atlanta. This first
step will be a safety trial using intensive ...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... control in children
aged 6 to 12 from the first
time point measured (1.5 hours) through 13
hours post-dose. VYVANSE is now the first
and only oral ADHD stimulant
treatment to ... as
they become available. Results from the first
of the three Phase 3
trials were positive, ...
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
... million, compared with $51.2 million for the first
six months of 2008. Product revenue for the six ... million, compared with $49.7 million for the first
six months of 2008.
Net loss for the six ... $8.6 million, compared with $10.7 million for the first
six months of 2008. Basic and diluted net loss ...
Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
All of the volunteers received their first
shot of the vaccine and, during the
three day ... 404 juvenile and 403 children, had received
shot of the vaccine through July 25. During the ... the Beijing municipal government(1) made its first
Panflu from Sinovac, with an initial ...
Hoya Announces First Quarter Financial Results for FY2010
announced financial results for the first
quarter ended June 30, 2009. Net
sales were 94.9 ... ended March 31, 2009.
Net income for the first
quarter was down 81.8%, to 3.8 billion ... to
the preceding quarter."
For the first
six months of FY2010 ending September 30, 2009, ...
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
... Intermezzo ((R)) has the potential to be the first
prescription sleep aid specifically approved for ... under the co-promotion option as early as the first
anniversary of the commercial launch of ... sublingual tablet) has the potential to be the first
prescription sleep aid specifically approved for ...
America's Organic Home-Fueling Movement Begins in Los Angeles
... Green Celebrities Attend World's first
E-Fuel MicroFuelerTM Installation
... of filling up your tank at home has arrived! The first
of the revolutionary portable home micro-refinery ... California.
GreenHouse introduced the first
E-Fuel MicroFueler TM at a premier debut event ...
ERT Reports Second Quarter 2009 Results
... million a year ago and $23.8 million for the first
quarter of 2009.
Gross margin percentage ... compared to 57.0% a year ago and 50.4% for the first
quarter of 2009.
Operating income margin ... compared to 30.3% a year ago and 14.0% for the first
quarter of 2009.
Net income was $2.5 ...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... treatment. We look forward to receiving the first
data from this trial by year-end 2009 and additional data in the first
half of 2010."
... group by year-end and additional data during the first
half of 2010; (v) expectations regarding the ...
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
... "On the strength of the momentum provided by our first
half results, coupled with what we now forecast ... (Divalproex), which Mylan launched in the first
quarter of 2009.
Total revenues from ... unfavorable impact of generic competition, which first
entered the market in 2007.
Sangamo BioSciences Reports Second Quarter 2009 Financial Results
... 30, 2008. Revenues were $7.9 million for the first
half of 2009, compared to $5.6 million in the ... operating expenses were $20.1 million for the first
half of 2009 and $22.4 million in the first
half of 2008. The decrease in operating expenses ...
Neurocrine Biosciences Reports Second Quarter 2009 Results
... $9.0 million, compared to $13.0 million for the first
half of 2008. We incurred a $2.2 million restructuring charge in the first
half of 2008 compared to a $0.7 million charge in the first
half of 2009. Additionally, other non-personnel ...
BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
... focus on the development of one of the nation's first
commercial-scale cellulosic ethanol facilities, ... next two years as we move toward bringing a first
commercial facility into production," said Carlos ... of technology being developed under the first
phase of the BP-Verenium partnership and brings ...
Sunesis Reports Financial Results for the Second Quarter 2009
... for the second quarter and $10.2 million for the first
half of 2009. As of June 30, 2009, cash, cash ... 10 to 15 percent. In the Bolus Schedule, both first
relapse and primary refractory patients are ...
General and administrative expenses for the first
three and six months of 2009 were $2.0 million ...
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
... obtain FDA approval for Tetrabenazine (TBZ), the first
drug ever licensed in the United States to treat ... a company with positive phase 2a data for a novel first
in class antiepileptic drug that will address ... allopregnanolone. It is being investigated as a first
in class treatment for epilepsy. Ganaxolone has ...
Sanofi-aventis Announces Second Quarter 2009 Results
... selected items. Consolidated net income for the first
half of 2009 was euro 2,637 million, versus euro 2,335 million for the first
half of 2008. Consolidated earnings per share for the first
half of 2009 was euro 2.02, against euro 1.78 for ...
Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division
... said Dr. Pilest. "To be among the first
to benefit from the newest drug and devise ... is given. If my enrolled patients can be the first
to experience a new solution, then that makes my ... experience spanning more than 30 years. He is a first
level trainer for the Fraxel Repair CO2 ...
Cynosure Reports Second Quarter 2009 Financial Results
... the same period of 2008 and $14.8 million in the first
quarter of 2009. The decline from the second ... aesthetic laser industry. The increase from the first
quarter of 2009 reflected a strengthening ... for the same period of 2008 and 60.9% in the first
quarter of 2009. The decline in gross margin in ...
GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles
... a high performance ethanol fuel for cars. The first
installation of the E-Fuel MicroFueler will be ... for the unit. "With the launch of the first
operational MicroFueler in Los Angeles, ...
Visuals Will Include:
Debut of the first
Hollywood locals fueling their cars ...
Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
... HSC human hair regrowth product for the first
time at the International Society of Hair ... proteins, growth factors and contains the first
naturally stabilized, bioactive solution of Wnt ... from existing follicles. Histogen's trial is the first
demonstration that compounds containing bioactive ...
UCR scientists manipulate ripples in graphene, enabling strain-based graphene electronics
... Ning (Jeanie) Lau and colleagues now report the first
direct observation and controlled creation of ... predicted theoretically, but Lau's lab is the first
to demonstrate and quantify the phenomenon ... the ripples in graphene sheets represents the first
step towards strain-based graphene engineering. ...
FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business
... A H1N1 (2009) Real Time RT-PCR test is the first
commercial lab test to be granted an emergency ... for the 2009 H1N1 influenza virus. It is also the first
test to qualitatively detect RNA of the pandemic ... Focus business, which has a track record of being first
to market with new laboratory testing services ...
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
... a 1.5% increase from the $1.34 reported for the first
six months of 2008. Excluding the negative ... and 19.4% increase for the second quarter and first
six months of 2009, respectively. A ... for all of 2009, believing that we can repeat our first
half performance for the remainder of the year, ...
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
... Disorder (ADHD) in children aged 6 to 12 from the first
time point measured (1.5 hours) up to the last ... Irvine. "These published data are the first
to have shown duration of effect of an oral ADHD ... improvement in children aged 6 to 12 from the first
time point measured (1.5 hours) up to 13 hours ...
Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
... a first-in-class treatment for anthrax, and the first
procurement under Project BioShield of a product ... 2009, HGS fulfilled its commitment to deliver the first
20,000 doses of raxibacumab to the Strategic ... HGS recognized $153.8 million in revenue in the first
quarter of 2009 from ...
Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
... for the ScoliScore(TM) AIS Prognostic Test - the first
test to determine the risk of progressive ... the risk of developing severe scoliosis and the first
molecular diagnostic for a spine disorder. GenDB ... the ScoliScore(TM) AIS Prognostic Test, the first
and only test that utilizes the genetic blueprint ...
Schering-Plough Reports Financial Results for 2009 Second Quarter
... was also launched in Canada in June as the first
once-monthly subcutaneous treatment;
In Animal Health, the launch of the first
vaccine against canine influenza virus, which was ... that a single injection of corifollitropin alfa, first
in the class of sustained follicle stimulants, ...
Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
... of 2%."
Wyeth also reported solid first
quarter 2009 results, confirming that its ... by geography, the Company generated 52% of its first
quarter revenue outside the United States and 60% of its first
quarter revenue from non-traditional ...
OpenQ Posts a 200% Revenue Growth in the First Half of 2009
... OpenQ announces solid revenue growth for the first
half of 2009 and is now serving 7 of the Top 10 ... posted a phenomenal 200% revenue growth in the first
half of 2009 as compared to the same time last year. The exceptional first
half results were driven primarily by new ...